Amplex increases the consideration in the cash offer to the shareholders and warrantholders of ADDvise and enters into agreements on conditional acquisitions of shares and warrants in ADDvise

Amplex AB has raised its all-cash offer for ADDvise to SEK 1.72 per class A/B share and SEK 0.52 per TO1A/TO1B warrant, valuing the company at ~SEK 1.1 billion based on 606,067,806 shares and 99,417,076 warrants. Amplex has secured conditional agreements with major shareholders representing ~21.11% of share capital (bringing combined control, undertakings and existing holdings to ~51.49% of share capital and ~60.57% of votes), includes a top‑up mechanism if a higher price is paid within six months, and requires regulatory approvals (including the Swedish Inspectorate of Strategic Products); the acceptance period expires 23 Jan 2026 with settlement expected around 30 Jan 2026.

Analysis

Market structure: Amplex’s conditional locks raise its control to ~51.5% of share capital and ~60.6% of votes, making a successful close highly probable and creating an effective takeover premium for public B-share liquidity (offer SEK 1.72 vs B close SEK 1.17 on 9 Dec = +47.5%). Winners: selling B-shareholders and TO1B warrantholders (large immediate cash premium). Losers: remaining A-shareholders (A closed at SEK 2.00; offer is ~14% discount) and public float holders facing delisting/liquidity risk if Amplex surpasses 90% and forces redemption.

Risk assessment: Key tail risks are (1) denial or delay of approvals by the Swedish Inspectorate of Strategic Products (blocking export/ownership-sensitive assets) before 23 Jan 2026, (2) competing higher bid (model: >SEK1.90 would force top-up payments and reprice stakes), and (3) post-close governance risk including compulsory redemption and delisting if Amplex >90% (likely within 6–12 months). Time buckets: immediate (days) = tender decision window to 23 Jan 2026; short-term (weeks) = regulatory outcome and settlement ~30 Jan; medium (6 months) = top-up window and potential re-offer; long (>1 year) = private restructuring and value realization.

Trade implications: Direct arbitrage — buy B-shares or TO1B warrants at market ≤SEK1.60/≤SEK0.20 and tender for near-term locked gain; set upper purchase limit at SEK1.70 and SEK0.40 respectively to preserve margin. Warrant strategy: tender TO1B (0.12→0.52) unless you model ADDvise public upside >200% within 6 months. Hedge: if holding A-shares, sell in market (capture ~SEK2.00) rather than accept SEK1.72 unless liquidity constrained; treat any post-acceptance <SEK1.80 as forced-sale threshold.

Contrarian angles: Consensus assumes no higher bidder — but top-up terms create incentive for a white‑knight to pay >SEK1.72 within six months to acquire residual float; a conditional rival at SEK2.00–2.20 could trigger secondary gains for initial sellers. Historical parallels: Nordic small-cap life-science take-privates often lead to 12–24 month value recovery post-restructure — opportunity for private-equity-like gains but illiquidity and execution risk are material. Monitor insider selling post-settlement and any acquisition financing announcements as leading indicators of restructuring pace.

Key Decisions for Investors

• If you own ADDvise class B shares, accept/tender into the offer by 23‑Jan‑2026 if you cannot source a competing bid >SEK1.90; otherwise establish a small buy-and-tender position (target 1–3% NAV) by purchasing B shares at ≤SEK1.60 and tendering for immediate arbitrage (~6–8%+ gross spread).
• If you hold ADDvise class A shares, DO NOT accept at SEK1.72 while market trades ≥SEK1.90–2.00; instead liquidate A shares on market (capture ~SEK2.00) or set an acceptance trigger to sell only if the market price falls below SEK1.80 or a competing bid appears ≥SEK2.10.
• Warrantholders (TO1B/TO1A): tender warrants into the offer — for TO1B the move from ~SEK0.12 to SEK0.52 is ~+0.40 absolute; buy TO1B at ≤SEK0.20 and tender for >100% upside, limit exposure to 0.5–1.5% NAV per account.
• Arbitrage/activist watch: build a small position in remaining public float B-shares only if you can obtain shares at ≤SEK1.65 and be prepared to hold through settlement (~30‑Jan‑2026); exit immediately on settlement. Use a max entry cap at SEK1.70 and cut loss at SEK1.50 if regulatory delay beyond 23‑Jan is announced.
• Risk control: reduce Swedish small-cap life‑science exposure by 1–2% of portfolio and set calendar alerts for two catalysts — Inspectorate decision by 23‑Jan‑2026 and six‑month top‑up expiry (first settlement + 6 months) — re-evaluate if competing bids or financing notices emerge.